(CercleFinance.com) – ViiV Healthcare, a global HIV company majority-owned by GSK, announces that it has reached an agreement with Gilead to settle ViiV Healthcare’s patent litigation relating to dolutegravir, a drug used in the HIV treatment.
Specifically, ViiV Healthcare, GSK and Shionogi accused Gilead’s Biktarvy of infringing some of their patents relating to dolutegravir.
The parties ultimately entered into a global settlement agreement and patent license agreement pursuant to which Gilead was granted a worldwide license to certain ViiV Healthcare patents relating to dolutegravir.
Gilead will make an upfront payment of $1.25 billion to ViiV Healthcare, in the first quarter of 2022. Gilead will then pay a 3% royalty on all future U.S. sales of Biktarvy ($6.09 billion in 2020) and any other product sold in the United States containing bictegravir.
Immediately after the transaction, patent infringement litigation in the United States, United Kingdom, France, Ireland, Germany, Japan, Korea, Australia and Canada will be dropped, says GSK.
Copyright (c) 2022 CercleFinance.com. All rights reserved.